
|Articles|January 6, 2005
FDA approves new oral agent for overactive bladder
The FDA has approved extended-release darifenacin (Enablex, 7.5 mg and 15 mg) for the treatment of overactive bladder.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Urologist describes early experience with gemcitabine intravesical system in NMIBC
2
Ronney Abaza, MD, discusses the next wave of advancements in robotic surgery
3
Ravi Chauhan, MD, discusses integrating nadofaragene into clinical practice
4
Joshua J. Meeks, MD, PhD, highlights dosing schedule advantage of nadofaragene in NMIBC
5




















